Clinical Trials in Würzburg, Germany
181 recruiting
Showing 1–20 of 242 trials
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled127 locationsNCT06890884
Recruiting
Phase 3
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation260 enrolled48 locationsNCT06006117
Recruiting
Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled200 locationsNCT07195695
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled84 locationsNCT07039916
Recruiting
Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi208 enrolled79 locationsNCT07170917
Recruiting
Phase 3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Parkinson DiseaseDystoniaEssential Tremor
Boston Scientific Corporation5,000 enrolled19 locationsNCT03664609
Recruiting
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
Essential Tremor
Boston Scientific Corporation500 enrolled20 locationsNCT04032470
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 2
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Acute Lymphoblastic Leukemia
Pfizer100 enrolled74 locationsNCT05748171
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
Movement DisordersParkinson DiseaseDystonia+1 more
Boston Scientific Corporation200 enrolled4 locationsNCT06553625
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Parkinson's Disease
Boston Scientific Corporation1,500 enrolled84 locationsNCT02071134
Recruiting
Vercise™ DBS Dystonia Prospective Study
Dystonia
Boston Scientific Corporation300 enrolled36 locationsNCT02686125
Recruiting
Phase 2
Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.
Patellofemoral osteoarthritis
University Hospital, Basel, Switzerland75 enrolled9 locationsNCT06163573